Introduction
Cancer immunotherapies targeting T cells, and particularly blocking immune checkpoints, are theoretically a promising option for tumor elimination, including glioma (1). However, not every patient responds equally to the treatment, the response being sometimes irrelevant or unexpectedly detrimental in dramatic cases (2) (3) (4) . Thus, exploring the behavior of T cells within the tumorigenic tissue and their cell-to-cell interactions becomes crucial to understanding immuno-oncology and better defining future immune-based therapeutics.
Activation of T cells requires physical contact with antigen-presenting cells (APCs) through the formation of the immunological synapse (IS) (5) . After antigen recognition by CD3/T cell receptor (TCR) complexes, T cells become activated and arrange a particular intercellular and symmetric interface with target cells, establishing a characteristic bull's eye structure, involving the segregation and clustering of a group of molecules and organelles (6, 7) . Importantly, as initially described by Kupfer, T cells organize a CD3/TCR-rich central supramolecular activation cluster (cSMAC) surrounded by lymphocyte function-associated antigen (LFA-1) that segregates to the periphery of the interface forming a ring-shape cluster, named peripheral-SMAC (pSMAC), surrounded as well by a CD45-enriched distal SMAC (dSMAC) (8) . Alternatively to IS engagement and as part of their life cycle, T cells dynamically patrol the environment and constantly search for antigens, maintaining a highly motile behavior until forming new stable contacts when antigen sensing is sufficient (9, 10) . In this
Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCRrich) central supramolecular activation cluster (cSMAC) is preferentially established with stromal cells, as opposed to malignant cells. Conversely, T cells in the malignant areas showed distinct morphometric parameters compared with nonneoplastic tissue -the former characterized by an elongated shape, well-suited to kinaptic dynamics. Importantly, high-resolution 3-dimensional analyses demonstrated the existence of bona-fide IK preferentially arranged in malignant areas of the tumor. This imbalance of IS/IK states between these 2 microenvironments reveals the low antigenic sensing of T cells when patrolling tumorigenic cells and reflects the immunoevasive environment of the tumor. motile state, described as immunological kinapse (IK) and interchangeable with stable IS, a particular subcellular distribution is arranged, formed by a leading lamellipodium, followed by a central lamella and a trailing uropod (11) . Hence, the TCR-rich cluster, corresponding to the cSMAC, is segregated to the posterior tail of the motile T cell, the uropod, whereas pSMAC molecules are distributed to the lamella (5) , adopting an asymmetric and directional shape. In this phase, the leading lamellipodium functions as a highly sensitive structure (12) dynamically searching for antigens in contrast with the static IS formation. Therefore, it is thought that T cells alternate between IS/IK states (a symmetrization and symmetry-breaking cycle), being 2 inter-convertible states that, when altered, could lead to immunopathology (5) .
Lymphocytes form stable contacts in tumors expressing their cognate antigen (13) , and -particularly -T cells that populate gliomas are able to engage with target cells to form bona-fide IS (14) . However, despite the SMAC formation, the cytotoxic effectiveness of T cells in malignant glioma or glioblastoma multiforme (GBM) is low or at least inefficient to eliminate the tumor (14) , along with a high profiling of Tregs that contributes to this low level of efficacy (15, 16) . Thus, in this pathological scenario, T cells may undergo small but pivotal alterations at the level of IS arrangement, or subsequent TCR signaling and activation, impeding their correct functioning. In fact, the biological significance of the Kupfer-type IS in glioma remains debated as to whether SMAC formation may be crucial for tumor clearance (17, 18) .
Importantly, many immunotherapies, such as the use of neutralizing antibodies against PD-1/PD-L1 immune checkpoint that target T cells, are thought to facilitate the formation of the IS (19) . In fact, PD-1 appears to be concentrated in IS (20) , forming microclusters at the cSMAC level to inhibit CD3/TCR receptor signaling through the phosphatase SHP2 (21) . This way, alterations at this molecular level could be key to enable immune escape.
To date, the visualization of subcellular clusters of T cells with enough resolution in human tissue remains challenging and scarcely explored, but it is clearly indispensable for fully understanding T cell kinetics, especially in current immuno-oncology research. Consequently, imaging immune synaptic interactions and T cell structural and motile cycles in solid tumors is essential to grasp its physiological meaning and especially to understand the potential imbalance of IS/IK states that may lead to immunopathology (5) .
Previous studies with fixed tissue multilabeling and 3-D imaging have facilitated the visualization of SMAC signatures in the brain (22) , including human glioma (14) ; however, the high resolution and volumetric visualization of kinapses in tissue, especially outside lymphoid organs, has been subtle.
In the present study, we postulate that T cells in tumorigenic areas may present a high ratio of motility and kinaptic characteristics, and we image in high resolution whether the balance of IS/IK is altered in the 2 distinct histological regions, neoplastic and nonneoplastic, of human glioma samples.
We focused our examination on high-grade glioma cases, which presented elevated infiltration of T cells and a substantial percentage of Tregs. Our 3-D imaging technology of biopsy-tissue blocks allowed the visualization of bona-fide IK with a high level of detail, showing particular morphometric parameters and TCR-rich uropods. These IK are especially frequent in malignant regions of the tumors in alternate balance with a low occurrence of IS. Interestingly, the opposite phenomenon, with inverted IK/IS balance, was seen in stromal areas.
Our results, demonstrating the presence and high frequency of IK in malignant areas of human GBM tissue, suggest the difficulty of T cells in recognizing antigens on glioma cells. Importantly, this contrasts with the high density of IS found in stromal areas, which implies an imbalance of IS/IK that may correlate with T cell anergy in tolerogenic states in GBM. Thus, the intervention in the dynamic states of glioma-infiltrated T cells may be critical to modulate T cell activation and/or anergy, representing fundamental aspects for designing effective immunotherapies.
Results
Elevated T cell infiltration is associated with highly proliferative gliomas. In order to study the IS/IK balance of T cells inside solid tumors, we analyzed the biopsies of a cohort of 15 glioma patients ranging from low-grade to high-grade glioma (Supplemental Table 1 ; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.120757DS1), considering the proliferation parameter Ki67 and standard glioma markers such as vimentin and glial fibrillary acidic protein (GFAP) expression, Figure 2B) . Fluorescence confocal microscopy revealed that T cells often accumulated at blood vessel edges but were also able to cross the endothelium and penetrate the tumor parenchyma (Supplemental Figure 2 , C and D). Stereological quantification of the samples revealed a significant increase of CD3 + T cell infiltration in parenchymal areas in contrast with vascular areas, in highly proliferative gliomas (Supplemental Figure 2, E-H) . Importantly, both T lymphocyte subpopulations CD8 + and CD4 + were seen homing into the tumors in the analyzed cohort of glioma samples (Supplemental Figure 3) . Conversely, as a control, patrolling T cells were scarcely seen in nonpathological human brain cortex and were only observed in apposition to vascular walls and protoplasmic astrocytes (Supplemental Figure 4) . Since the significant homing of T cells was associated with highly proliferative gliomas, we focus on the subgroup of biopsies from patients classified as grade IV gliomas or GBM for the following 3-D high-resolution analyses.
Parenchyma-infiltrated CD3 + T cells populate malignant and stromal areas establishing cellular contacts. In order to elucidate the particular dynamics of infiltrated lymphocytes within the tumor tissue, we analyzed with fluorescent multilabeling the intercellular appositions of CD3 + T cells comparing malignant with stromal areas. Since microglia/macrophages are the preeminent cell filling GBM stroma (23), we used antibodies against GFAP to label neoplastic glioma cells, massively populating malignant areas, and antibodies against HLA-DR (human form of MHCII) to label nonneoplastic microglia/ macrophages populating the stroma (Supplemental Figure 5A ). Additionally, we confirmed the identity of MHCII + cells as microglia/macrophages using antibodies against Iba-1 (Supplemental Figure 6 ). Three-dimensional transparencies of tissue blocks revealed that both tumorigenic malignant areas (GFAP-rich) and stromal areas (MHCII-rich) of the tumor were highly infiltrated by CD3 + T cells ( Figure 1A and Supplemental Videos 1 and 2). More importantly, detailed microscopic analyses demonstrated that infiltrated lymphocytes frequently interacted with either GFAP + or MHCII + cells ( Figure 1 , B and C). For this analysis, we ruled out the possibility of using an anti-vimentin antibody because, despite marking tumor cells, it also labels microglia/macrophages (Supplemental Figure 5D ), and it is not possible to distinguish tumorigenic cells from stromal cells with this marker. We also verified at the malignant-stromal intersections that GFAP + tumor cells do not express detectable levels of MHCII, demonstrating that both markers label clearly distinct populations of cells (Supplemental Figure 5 , B and C). Confocal and electron microscopy reflected intimate and membrane-to-membrane appositions of T cells with both glioma cells ( + T cells, suggesting that this activation may favor the increase of the regulatory arm, we also analyzed the percentage of population of Tregs within the tumor in our biopsy cohort using FOXP3 + immunostaining. We observed the presence of Tregs in the tumors with an increased percentage in highly anaplastic cases (Supplemental Figure 7) .
Infiltrated T cells preferentially show kinetic morphology in GFAP areas.
Considering that decreased levels of IS formation would be balanced with an increase of kinapses (19) , and because a reduced antigen engagement may result in higher motility of the cells (9), we analyzed the morphometric aspects of T cells in tumorigenic GFAP-rich areas to compare with stromal MHCII-rich sites. T cells in abundant glioma cell locations show a distinctive kinetic morphology characterized by a typical elongated shape ( Figure 7A ), where in some cases, a leading lamellipodium and a trailing uropod can be appreciated ( Figure 7B ). Morphometric analyses of our captured data revealed significantly reduced roundness, together with an increased aspect ratio ( Figure 7 , C-F) in T cells of GFAP-rich tumorigenic locations, compatible with higher restlessness and reduced antigen-engagement; this is in contrast with MHCIIrich sites, where T cells appear rounded, compatible with static IS and higher frequency of antigen engagement. This increase of kinaptic morphology in malignant areas is consistent with a dynamic desensitization to antigens (24) , and it could be facilitated by the expression of immune checkpoints on glioma cells, such as PD-L1 (25, 26) , which is an immune suppressive pathway in tumors (27) and induces the TCR-stop signal, in contrast with CTLA-4 (28) . of CD3 and the architecture of the kinapse, especially regarding the high spreading and intensity of CD3 at the trailing uropod ( Figure 8D , and Supplemental Video 6). Interestingly, the indentation of the T cell nucleus appears oriented to the back of the cell ( Figure 8E ), corresponding to the location of the microtubule-organizing center (MTOC) and the Golgi, as previously defined in vitro (29) . We quantified the T cells exhibiting a characteristic kinapse, including the T cells presenting a CD3-high fluorescent uropod, evidenced by the rainbow intensity scale, in both malignant and stromal areas ( Figure 8F ). We observed strong significant differences between the 2 GBM areas ( Figure 8F ), with the proportion of bona-fide IK in malignant areas being dramatically higher than in stromal areas. Since malignant areas lacked MHCII, we hypothesized that cytotoxic T lymphocytes (CTLs) would be preferentially located in this tumor environment. After corroborating the expression of CD3 by CD8 + T cells with double immunolabeling (Supplemental Figure 8A) , we examined the presence of 
CD8
+ T cells in the malignant areas. We observed a wide distribution of CTLs within the GFAP-rich tumor parenchyma (Supplemental Figure 8B ), which were frequently seen interacting with glioma cells and showing kinaptic shape (Supplemental Figure 8, C-E) . To rule out whether only CTLs were populating malignant areas, we multiple labeled the samples with CD3, CD8, and GFAP. We observed that both CTLs and non-CTLs were present in GFAP-rich areas, showing morphologies compatible with kinaptic dynamics (Supplemental Figure 9) .
Discussion
This study demonstrates that characteristic IK are formed in vivo in humans, and it shows that the balance with their symmetric phase, the IS, can be altered in pathological conditions. The high IK frequency seen in malignant GBM areas indicates that T cells may experience anergy, entering a tolerogenic state preventing tumor immunity.
Our report shows that T cells, including CD8 and CD4 subsets (Supplemental Figure 3) , vastly infiltrate the tissue in high-grade proliferative gliomas in concordance with previous knowledge (30) but implying tangible parenchymatose homing and endothelial crossing (Supplemental Figure 2) . Importantly, T cells populate both malignant and stromal areas of the tumor ,as visualized in tissue block confocal transparencies (Figure 1; Supplemental Videos 1 and 2) . High-resolution zoom-in confocal scanning and electron microscopy demonstrated that parenchyma-infiltrated T cells closely interact with neoplastic and nonneoplastic cells on a membrane-to-membrane basis (Figure 2) , compatible with antigen-mediated interaction. Thus, we analyzed the TCR/CD3 polarization, characteristic of IS signature forming cSMAC, in the intercellular space with neoplastic (glioma cells) or nonneoplastic cells (tumor-associated macrophages; TAMs) ( Figures 3, 4 , and 5, and Supplemental Videos 3 and 4). Besides cSMAC visualization, other characteristics of in-tissue IS were seen, as we already demonstrated in previous findings (14, 22) , including flat interface or oriented nuclear indentation toward the target cell. However, the quantification of IS events revealed that cSMAC formation was much more frequent (more than double) with stromal cells than with malignant cells, despite similar levels of interaction (Figure 6 ), revealing the difficulty of T cells to recognize antigens on the glioma cell surface. Importantly, T cells within the neoplastic parenchyma, in contrast with the stroma, show elongated morphology, suggesting high motility and migration compatible with kinaptic dynamics, neoantigen search, and tumor evasion (Figure 7) . By utilizing our recently published technique (31), we were able to discern IK in human tissue displaying the characteristic triangular shape with a leading lamellipodium and a TCR/CD3-rich trailing uropod ( Figure 8 ). We could also appreciate that the typical nuclear indentation, which is known to host the Golgi apparatus, the MTOC, and cytolytic granules (32-34), appears oriented toward the uropod as described in previous studies in vitro (29, 35) .
The presence of frequent IK in neoplastic GBM areas reflects poor TCR sensing that can be due to several factors. First, the tangible increase in IS with stromal myeloid cells could imply tolerance induction. Actually, MHCII-type prolonged engagements could be tolerogenic for T cells. Recent studies performed in an autochthonous model of breast cancer show that T cells are arrested by TAMs shortly after tumor entry, later becoming increasingly motile, suggesting reduced TCR signaling (24) . This is compatible with our results where a primary engagement of T cells with myeloid microglia/ macrophages in GBM, especially CD4 + T cells in MHCII-rich perivascular stroma, may induce an antigen desensitization reflected later in malignant areas. Secondly, besides the previous sensitization taking place by T cell arrest in stromal areas, T cell crawling in neoplastic tissue may also be facilitated by the expression of PD-L1 by tumor GBM cells, which has been observed in some GBM cases (1, 25) . However, the consistency and degree of PD-L1 expression by glioma cells still remains controversial and scarcely studied (4) . Previous reports in other scenarios have shown that PD-1/PD-L1 interactions promote tolerance by blocking TCR stop signal (28) , which is compatible with the IK triggering. This is apparently a very dynamic process in which PD-1 is clustered at the IS cSMAC level (20) and able to inhibit CD3/TCR receptor signaling (21) . At this point, coinhibitory receptor PD-1 may play a critical role in preventing the stabilization of IS, especially when encountering high levels of tumor cell ligand PD-L1 (36) . In this context, weak PD-1/PD-L1 interactions might favor symmetric SMAC, stopping T cell motility, whereas strong PD-1/PD-L1 binding may induce T cell anergy (37, 38) , breaking the symmetry of the SMAC (11) and, thus, promoting IK.
We found that both CTLs and non-CTLs populate the GFAP-rich malignant areas displaying kinaptic shape (Supplemental Figure 9 ). More generally, and in the light of our findings, CD8 + T cells -after reaching the tumor parenchyma -would directly engage with glioma cells as motile IK (Supplemental Figure 8) , scarcely forming IS, whereas CD4 + T cells -after being arrested at MHCII populated areas with solid IS -may later enter the malignant environment with an IK motile behavior similarly to their CD8 T CTLs counterparts (Supplemental Figures 3 and 9) . These results indicate that tumorigenic cells may escape immunity by locally preventing the formation of IS, but also by favoring antigen presentation by stromal TAMs, which could increase the antigen-specific regulatory arm toward tolerance. High MHCII interactions within the tumor suggest the increase of CD4-type infiltration (Supplemental Figure  3) and activation, including Tregs, which we have seen populating our GBM samples ( Supplemental Figure 7) . The increased proportion of Tregs could be due, on the one hand, to the activation or switching enabled by the tumor microenvironment (i.e., cytokines such as TGF-β) (39) , or, on the other hand, to the induced CD4 + T cell anergy, able to generate Treg precursors by the hypomethylation of particular genes to differentiate FOXP3 Tregs (40) . In addition, it is thought that FOXP3 expression could also be promoted by PD-L1 interactions through AKT/mTOR signaling inhibition, acting like a molecular switch to transform naive T cells into Tregs (41) . All strategies are putatively designed to promote tumor immunity by diminishing the cytotoxic T cell response.
In this context, it is important to consider that PD-L1 and Tregs are critical elements in immune tolerance, as it is likely that levels of both factors may be closely connected with cancer patients' survival, including glioma (1, 42) , in which higher expression of PD-L1 has been correlated with a worse outcome (43) . Although GBM shows Treg accumulation (44) , a direct relation with clinical prognosis is still unclear (45) . Despite the success of immunotherapy blocking immune checkpoint PD-L1/PD-1 in some particular cases (4), the mechanisms of action -and particularly its role in malignant glioma -remains undecided (46) . Nevertheless, it is critical to ponder whether PD-L1 may have a pivotal role in the induction and maintenance of Tregs (41), as well as T cell anergy.
The fact that infiltrated T cells display a dramatically higher proportion of kinapse arrangement in malignant areas is compatible with a random walk in search for neo-antigens, which also implies that the motility of T cells is not impaired but rather promoted in GBM. The differential kinetics between malignant and stromal areas indicates that neoplastic cells present characteristics to induce immune evasion. Factors like PD-L1 may break the IS symmetry, facilitating the T cells passing through these tumor regions. This suggests that T cells have difficulties in seeing or finding neo-antigens on the tumor cell surface, enabling immune escape of glioma at the antigen-sensing level. Therefore, as blocking PD-L1 may be effective in some circumstances, strategies also targeting TCR/CD3 such as chimeric antigen receptor (CAR) T cells or CD19/CD3 bispecific T cell engagers (BiTE) should be further explored for killing tumors (47) (48) (49) . In this setup, the intervention at the IS and IK levels, modulating TCR/CD3 dynamics in T cell cycle, may be crucial for designing an effective antibody-based immunotherapy. 
Methods

Patients and samples
Biopsies from 15 patients, admitted to the General Hospital of Valencia (Valencia, Spain), diagnosed with glioma were used for this research project (Supplemental Table 1 ). None of the patients received immunotherapy treatments. Tumors were excised and prepared following the protocol described in a previous publication (14) and approved by the 2 institutions involved, including the Ethics Committee on Animal and Human Research of the Universitat Autònoma de Barcelona (Bellaterra, Barcelona, Spain) and the Research Committee of the General Hospital of Valencia, which included the informed consent of the patients. This procedure requires the immediate fixation of biopsies after resection, allowing the preservation of the microstructure. After fixation, samples were cryoprotected and sectioned in a cryostat (Leica Microsystems). The pathology department of the hospital provided the diagnosis and grade, including the Ki67 proliferation index. Samples showed the typical features of glioma: marked cellularity with hyperchromatism and pleomorphism, gemistocytic differentiation, glomeruloid vessels, necrotic palisades, and aberrant mitoses (Supplemental Figure 1) .
Histological evaluation
Histochemistry. Thionine staining was performed to evaluate the typical structural pathological features of glioma in the samples. All the samples were first mounted on gelatinized slides, dried and then rinsed in distilled water, stained in thionine solution for 5 minutes, washed in distilled water, dehydrated in increasing concentrations of ethanol (70%, 80%, 90%, and 100%; Fluka Analytical), and fixed in xylene (Thermo Fisher Scientific). Then sections were cover-slipped to be analyzed with the conventional light microscope (Eclipse 80i microscope, Nikon), taking the required pictures with the digital camera connected to the microscope (DXM 1200F Digital Camera, Nikon). IHC. Free-floating IHC by DAB detection was performed on 60 μm-thick tumor sections to visualize immune-cell markers and glial-tumor cell markers, using primary antibodies to recognize: GFAP (1:500, mouse IgG1, clone GA5, MAB360; MilliporeSigma); CD3 (1:100, rabbit polyclonal, A0452; Dako); Vimentin (1:100, mouse IgM, clone LN-6, V2258; MilliporeSigma); FOXP3 (1:2, mouse IgG1, clone 236A, Lot 117; CNIO); CD8 (1:20, mouse IgG2b, clone 4B11, MCA1817; AbD Serotec); CD4 (1:20, mouse IgG1, clone 1F6, NCL-CD4-1F6; Novocastra); and HLA-DP, -DQ, and -DR (1:100, mouse monoclonal, clone CR3/43, M0775; Dako). Samples were first treated with citrate (10 mM, pH 6, 60°C, 20 minutes) to increase antigen retrieval and antibody penetration. Then, 0.3% hydrogen peroxide was used to inactivate endogenous peroxidase, and sections were blocked for 1 hour with 0.5% Triton X-100 with 10% horse serum (MilliporeSigma) before incubating for 48 hours with primary antibody diluted in TBS-0.5% Triton X-100, 1% horse serum, and 0.1% sodium azide. The primary antibodies used are described above. Secondary antibodies were biotinylated goat anti-mouse (1:1,000, goat IgG; BA-9200, Vector Laboratories) or biotinylated goat anti-rabbit (1:1,000, goat IgG; BA-1000, Vector Laboratories), diluted in 0.5% Triton X-100 with 1% horse serum and 0.1% sodium azide, according to the host of the primary antibodies. Secondary antibodies were detected by using the Vectastain Elite ABC HRP and DAB HRP Substrate Kits (Vector Laboratories). Sections were mounted on gelatinized glass slides and were dehydrated through graded ethanol solutions (70%, 80%, 90%, and 100%) and xylene before coverslipping.
Stereology and quantification. The number of Vimentin + cells, T cells (CD3   +   ) , and FOXP3 + Tregs immunostained with DAB was quantified using stereological methods in serial sections. Conventional microscope (Nikon EclipseTe2000e) with a motorized stage (Prior ProScan II) and connected to a high-resolution digital camera (Hamamatsu, Orca-ER) was used to systematically sample each tumor section. Pictures were taken automatically and homogeneously over the section using specialized image-analysis software (Metamorph, Molecular Devices) with the 40× oil objective. For each section, we established the X and Y coordinates of a conventional rectangle covering the section surface. This rectangle was divided into a number of columns and rows necessary to obtain the sufficient number of sample-frames for the quantification, establishing a minimum of 25 frames per section. Once the pictures were taken, we counted the positive cells with image analysis software (ImageJ version 1.47, NIH) following stereological criteria. We considered each picture as a physical dissector for stereological quantification of particles in focus in 1 Z optical plane. For T cells, all the cells that appear inside the field were counted except for the ones hitting the left and top border of the physical dissector. We distinguished the vascular and parenchymal dissectors following the criteria of previously published protocols (50) . For vimentin + cells, we used a stereological grid and only the cells touching the crossing of the grid were counted, as previously described (51) 
Detection of IS/IK in 3-D in tissue
Immunofluorescence in tissue blocks. To visualize the microanatomical details of IS in thick tissue sections, we followed the protocol that we recently published (31) . In summary, free-floating immunolabeling was performed on 60 μm-thick sections for multiple staining to visualize 3-D CD3 + T cells in combination with either GFAP + cells or MHCII + cells (HLA-DP, DQ, DR + cells in humans). The samples were pretreated with hot citrate buffer to ameliorate antibody binding and antigen retrieval. Next, nonspecific antibody binding sites were blocked during 45 minutes with 0.5% Triton X-100 with 10% horse serum (MilliporeSigma) before incubating 48 hours with primary antibody diluted in 0.1% horse serum in TBS-0.5% Triton X-100, 0.1% sodium azide. The primary antibodies used were anti-human CD3 (1:100, rabbit polyclonal, A0452; Dako); anti-human CD8 (1:25, mouse IgG1, clone 144B, ab17147; Abcam), anti-CD31 (1:200, mouse IgG1, clone C31.3 + JC/70A, ab199012; Abcam), and anti-GFAP (1:500, mouse IgG1, clone GA5, MAB360; MilliporeSigma) or anti-GFAP (1:200, chicken polyclonal, ab4674; Abcam), anti-HLA-DP, DQ, DR (1:100, mouse monoclonal, clone CR3/43, M0775; Dako), anti-Iba-1 (1:500, rabbit polyclonal, 019-19741; WAKO), and anti-vimentin (1:100, mouse IgM, clone LN-6, V2258; MilliporeSigma). Secondary fluorescence antibodies, diluted in 0.5% Triton X-100 with 1% horse serum and 0.1% sodium azide, were used accordingly with the host of the primary antibodies for the subsequent detection. The secondary antibodies used were AlexaFluor 488 goat anti-rabbit IgG (1:1,000), AlexaFluor 488 goat anti-mouse IgG1 (1:1,000), AlexaFluor 555 goat anti-chicken IgG (1:1,000), AlexaFluor 555 goat anti-mouse IgG (1:1,000), and AlexaFluor 555 goat anti-mouse IgG (1:200). In the case of MHCII staining, AlexaFluor 555 goat anti-mouse IgM (1:1,000) and AlexaFluor 647 goat anti-rabbit IgG (1:1,000) were used. Then, DAPI (1:1,000) was used to stain the nuclei of the cells. Sections were mounted on glass slides and coverslipped using Prolong antifade reagent (Invitrogen).
Confocal analysis of human tissue. The percentage of CD3 + cells establishing IS or IK with either GFAP + tumorigenic cells or MHCII + cells were quantified in confocal stacks. Human biopsies were imaged with a high-resolution confocal microscope (Zeiss Examiner D1 AX10) with a 40× oil objective and managed with confocal software (ZEN, Zeiss). Stacks covering several layers of T cells were taken with an optical section interval of 0.5 μm, visualized with Illucida FX software (Illucida), and analyzed with the image analysis software ImageJ. Five hundred and sixty-eight interacting T cells were analyzed for GFAP apposition, whereas 456 interacting T cells were analyzed for MHCII cells. We counted separately the total number of T cells in every stack; the total number of contacts were categorized by the display of specific features of active IS such as contacts in which the T cell shows an oriented flat interface and those in which a CD3-rich cSMAC was clearly visible with the rainbow spectrum tool (intensity fluorescence scale). After the analysis, representative examples of those showing the specific features of IS were imaged in detail with the appropriate zoom-in scanning. More details of the confocal imaging protocol can be found in a recent publication (31) .
3D visualizations and reconstructions
To visualize confocal-scanned tissue blocks in transparencies and 3-D-based patterns, we used a developed software application able to display the shape and architectural location of T cells, rapidly and in the whole analyzed space, as well as visualizing the T cell position in relation to other cell types (IllucidaFX). This Apple-based application applies shadowing and noise filtering, and it allows the visual adjustment of z axis to correct fixed tissue flattening (31) . For particular cells and interactions, we decided to use another software application (Imaris 8.0. Bitplane) that allows the optical isolation of a particular cell and the building of different iso-surfaces to better understand the microarchitecture of the labeled structures. In this case, each fluorophore and level of fluorescence can be individually rendered with high resolution.
Electron microscopy
Thick sections of biopsies were post fixed with 2% paraformaldehyde and 2.5% glutaraldehyde. Tumor sections were contrasted with 2% sodium tetroxide, dehydrated, stained in 2% uranyl acetate, and embedded in Durcupan resin (Fluka; MilliporeSigma). Semithin sections (1.5 μm) were cut with a diamond knife and stained with 1% toluidine blue for light microscopy. Ultrathin sections (70 nm) were cut and stained with lead citrate. Grids were then examined using a FEI Tecnai G2 Spirit transmission electron microscope (FEI Europe) and a digital camera (Morada Soft Imaging System; Olympus).
Statistics
The results were expressed as mean ± SEM and percentages. We first tested the normality for each group by the Shapiro-Wilk normality test. Depending on the normality test results, each parameter was evaluated either by (a) 2-tailed t test for 2 independent samples in the case of normal groups or by (b) Mann-Whitney U test for 2 independent samples in the case of nonnormal groups. In all cases, P ≤ 0.05 was considered significant.
Study Approval
Studies were approved by the Ethics Committee on Animal and Human Research of the Universitat Autònoma de Barcelona (Bellaterra, Barcelona, Spain) and the Research Committee of the General Hospital of Valencia, which included the informed consent of the patients.
